Type: Press Release
Cardiogenic Shock Survival Rates Improve Significantly in Three Years Since Impella FDA PMA Approval
… was 51% in the United States1 Today Impella heart pumps combined with the adoption of best practices which include … This clinical data combined with the FDA post-approval studies embedded in Abiomed’s prospective cVAD Study helped … survival Survival to discharge was 68% 46% 35% 35% and 26% for patients requiring 0 1 2 3 and ≥4 inotropes before …
Type: Press Release
… first quarter fiscal 2014 revenue of $427 million up 10% compared to revenue of $388 million in the same period of … year period Compared to the prior year the loss included $26 million of incremental legal expenses related to the … in capital 420674 414810 Accumulated deficit (259984) (258261) Treasury stock at cost - 1206367 shares at June 30 2013 …
Type: Press Release
… to implement guideline-informed care based on the recommendations to enable better patient outcomesImpella the … trial to achieve its primary survival endpoint and showed a 26% overall relative risk reduction with a number needed to … dialysis remained on dialysis at six months6 Previous studies have demonstrated that STEMI-related cardiogenic shock …
Type: Press Release
… $277 million an increase of 10% or 12% in constant currency compared to $253 million in the same period of the prior fiscal year Worldwide product revenue of $264 million an increase of 10% or 12% in constant currency … the US product revenue of $49 million an increase of 11% or 26% in constant currency compared to $44 million in the same …
Type: Press Release
… rates in cardiogenic shock is reproducible in academic and community hospitals across the United States Results were … selection criteria that mimicked prior cardiogenic shock studies23 Patients included in the study were treated between … survival Survival to discharge was 68% 46% 35% 35% and 26% for patients requiring 0 1 2 3 and ≥4 inotropes before …
Type: Press Release
… fiscal 2018 revenue of $1325 million an increase of 29% compared to revenue of $1030 million for the same period of … of $560 million to $575 million an increase in revenue of 26% to 29% from the prior year This compares to the prior … net 53557 54055 Inventories 36926 34931 Prepaid expenses and other current assets …
Type: Press Release
… fiscal fourth quarter 2015 revenue of $676 million up 34% compared to revenue of $504 million in the same period of … in fiscal year 2014 GAAP net income was $1137 million or $265 per diluted share compared with $74 million or $018 per … year Full year US Impella revenue totaled $1915 million up 26% compared to $1520 million in the prior year An …
Type: Press Release
… fourth quarter fiscal 2013 revenue of $437 million up 17% compared to revenue of $373 million in the same period of … or $009 per diluted share compared to GAAP net income of $26 million or $006 per diluted share in the prior year For … 2013 total revenue was $1581 million up 25% compared to $1264 million for fiscal year 2012 and GAAP net income was …
Type: Press Release
… fiscal 2017 revenue of $1247 million an increase of 33% compared to revenue of $940 million for the same period of … 54055 42821 Inventories 34931 26740 Prepaid expenses and other current assets 8024 6778 Total current assets 326958 288392 Long-term marketable securities …
Type: Press Release
… fiscal 2015 revenue of $519 million an increase of 17% compared to revenue of $443 million for the same period of … the Impella 25 PMA submission includes two FDA approved studies PROTECT I and PROTECT II totaling 472 patients which … Issued - 41831077 shares at September 30 2014 and 41122695 shares at March 31 2014 Outstanding - 40577134 shares …